

Our Vision

We strive to be a leading enterprise in the global pharmaceutical and healthcare markets.

Our Mission

Better health for families worldwide.

Contents

02	Introduction
04	Chairman's Report
05	Management Report
43	Financial Statements
50	Notes to the Financial Statements
51	Statement of Directors
52	Statement of Directors (continued)
54	Statement of Directors (continued)
56	Statement of Directors (continued)
58	Statement of Directors (continued)
91	Appendix

Corporate

Directors

Executive Director

吳以芳 (Wu Yifang)
()

Non-executive Directors

陳啟宇 (Chen Qiyu)
姚方 (Yao Fang)
徐曉亮 (Xu Xiaoliang)
龔平 (Gong Ping)
潘東輝 (Pan Donghui)
張厚林 (Zhang Houlin)

Independent Non-executive Directors

李玲 (Li Ling)
湯谷良 (Tang Guliang)
王全弟¹ (Wang Quandie)
余梓山¹ (Yu Zishan)
江憲² (Jiang Xian)
黃天祐² (Huang Tianyou)

Supervisors

任倩 (Ren Qian)
曹根興 (Cao Genxing)
管一民 (Guan Yimin)

Joint Company Secretaries

董曉嫻 (Dong Xiaoyan)
甘美霞 (Gan Meixia)

Authorized Representatives

吳以芳 (Wu Yifang)
甘美霞 (Gan Meixia)

Strategic Committee

陳啟宇 (Chen Qiyu)
吳以芳 (Wu Yifang)
姚方 (Yao Fang)
徐曉亮 (Xu Xiaoliang)
李玲 (Li Ling)

Audit Committee

湯谷良 (Tang Guliang)
王全弟¹ (Wang Quandie)
龔平 (Gong Ping)
江憲² (Jiang Xian)

Nomination Committee

王全弟¹ (Wang Quandie)
李玲 (Li Ling)
潘東輝 (Pan Donghui)
江憲² (Jiang Xian)

Remuneration and Appraisal Committee

余梓山¹ (Yu Zishan)
湯谷良 (Tang Guliang)
王全弟¹ (Wang Quandie)
陳啟宇 (Chen Qiyu)
潘東輝 (Pan Donghui)
江憲² (Jiang Xian)
黃天祐² (Huang Tianyou)

Environmental, Social and Governance Committee

余梓山¹ (Yu Zishan)
李玲 (Li Ling)
吳以芳 (Wu Yifang)
黃天祐² (Huang Tianyou)

Registered Office

10
2000 3,

Principal Place of Business in the PRC

12
200233,

¹ 11 2021
² 11 2021

Principal Place of Business in Hong Kong

Unit 4, Level 13, Block 3, The Gateway, 182 Queen's Road East, Hong Kong

Legal Advisers in Hong Kong

Deacons & Partners

Legal Advisers in the PRC

Wang & Partners (P.R.C.)

Auditors

Deloitte & Touche

Principal Banks

Bank of China Limited
 Citibank N.A.
 HSBC Bank plc
 Industrial and Commercial Bank of China Limited
 The Hongkong and Shanghai Banking Corporation Limited

Company Name

China Resources Gas Group Limited (Incorporated in Hong Kong)*

Stock Abbreviation

CRG

Share Listing

China Resources Gas Group Limited (H Shares)
 001
 China Resources Gas Group Limited (A Shares)
 021

A Share Registrar and Transfer Office in the PRC

China Resources Gas Group Limited & China Resources Gas Group (Holding) Limited (Incorporated in Hong Kong)
 Unit 1101, 11/F, The Gateway, 182 Queen's Road East, Hong Kong

H Share Registrar and Transfer Office in Hong Kong

China Resources Gas Group Limited
 Unit 4, Level 13, Block 3, The Gateway, 182 Queen's Road East, Hong Kong

Company's Website

http://www.crghk.com.hk

Financial

0.0.

For the six months ended 30 June

	2021 RMB million	2020 "
Operating results		
Revenue	16,878	13,422
Cost of sales	(8,767)	(7,114)
Gross profit	1,343	1,222
Operating expenses	(3,304)	(2,302)
Operating profit	2,482	1,111
Finance income	4,670	3,111
Profitability		
Operating profit margin	51.94%	4.4%
Operating profit margin excluding pharmaceutical manufacturing segment	7.96%	2.2%
Operating profit margin excluding pharmaceutical manufacturing segment and finance income	16.32%	13.1%
Earnings per share ()		
Operating profit	0.97	0.41
Operating profit excluding pharmaceutical manufacturing segment	0.97	0.41
Of which: Pharmaceutical manufacturing segment		
Revenue	12,179	10,212
Cost of sales	7,072	5,111
Gross profit	1,353	1,111
Operating expenses	1,257	1,111

	30 June 2021 RMB million	31 2020 "
Assets		
Property, plant and equipment	88,422	83,212
Intangible assets	37,804	33,311
Investments in subsidiaries	41,383	33,022
Investments in associates	10,489	10,211
Other assets	46.80%	40.0%

Management

SELLING AND DISTRIBUTION EXPENSES

During the reporting period, the Company's selling and distribution expenses were RMB 43 million, an increase of 104.4% over the same period in 2020.

R&D EXPENSES AND R&D EXPENDITURE

During the reporting period, the Company's R&D expenses and R&D expenditure were RMB 1,432 million, an increase of 1.1% over the same period in 2020. R&D expenses accounted for 3.3% of the Company's net sales, and R&D expenditure accounted for 1.31% of the Company's net sales. The Company's R&D expenses and R&D expenditure were RMB 1,432 million, an increase of 1.1% over the same period in 2020. R&D expenses accounted for 3.3% of the Company's net sales, and R&D expenditure accounted for 1.31% of the Company's net sales.

SHARE OF PROFITS OF ASSOCIATES

During the reporting period, the Company's share of profits of associates was RMB 2 million, a decrease of 32.4% over the same period in 2020.

PROFIT FOR THE PERIOD

During the reporting period, the Company's profit for the period was RMB 2,441 million, an increase of 44.1% over the same period in 2020. The Company's profit for the period was RMB 2,441 million, an increase of 44.1% over the same period in 2020.

PROFIT FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

During the reporting period, the Company's profit for the period attributable to owners of the parent was RMB 2,442 million, an increase of 44.1% over the same period in 2020. The Company's profit for the period attributable to owners of the parent was RMB 2,442 million, an increase of 44.1% over the same period in 2020.

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts

As at 30 June 2021, the Group's total debt was 2,213 million HK dollars (2020: 23,433 million HK dollars), of which 30% (2020: 31%) was denominated in US dollars. The Group's total debt was 2,213 million HK dollars (2020: 23,433 million HK dollars) as at 30 June 2021, of which 665 million HK dollars (2020: 10,422 million HK dollars) was denominated in US dollars. The Group's total debt was 2,213 million HK dollars (2020: 23,433 million HK dollars) as at 30 June 2021, of which 665 million HK dollars (2020: 10,422 million HK dollars) was denominated in US dollars.

As at 30 June 2021, the Group's total debt was 2,213 million HK dollars (2020: 23,433 million HK dollars), of which 665 million HK dollars (2020: 10,422 million HK dollars) was denominated in US dollars. The Group's total debt was 2,213 million HK dollars (2020: 23,433 million HK dollars) as at 30 June 2021, of which 665 million HK dollars (2020: 10,422 million HK dollars) was denominated in US dollars.

As at 30 June 2021, the Group's total debt was 2,213 million HK dollars (2020: 23,433 million HK dollars), of which 665 million HK dollars (2020: 10,422 million HK dollars) was denominated in US dollars. The Group's total debt was 2,213 million HK dollars (2020: 23,433 million HK dollars) as at 30 June 2021, of which 665 million HK dollars (2020: 10,422 million HK dollars) was denominated in US dollars.

	30 June 2021	31 2020
Cash and cash equivalents denominated in:		
US dollars	7,269	,214
HK dollars	164	,1 4
Other currencies	2,564	,30
	72	41
	420	20
	10,489	, 2

Gearing Ratio

As at 30 June 2021, the Group's gearing ratio was 2.1% (2020: 2.3%). The Group's gearing ratio was 2.1% (2020: 2.3%) as at 30 June 2021. The Group's gearing ratio was 2.1% (2020: 2.3%) as at 30 June 2021.

Interest Rate

As at 30 June 2021, the Group's interest rate was 11.03% (2020: 11.03%). The Group's interest rate was 11.03% (2020: 11.03%) as at 30 June 2021. The Group's interest rate was 11.03% (2020: 11.03%) as at 30 June 2021.

Management

Maturity Structure of Outstanding Debts

	30 June 2021	31 2020
1	15,992	14,40
2	2,847	0,01
3	4,564	4
4	1,810	4
	25,213	23,43

Available Facilities

30 June 2021, the available facilities were 10,4 million RMB, of which 34,3 million RMB were used for bank loans, 10,4 million RMB for bank credit lines, and 0,1 million RMB for other facilities.
30 June 2021, the available facilities were 0,1 million RMB, of which 1,41 million RMB were used for bank loans, and 0,1 million RMB for other facilities.

Collateral and Pledged Assets

30 June 2021, the collateral and pledged assets were 1,11 million RMB, of which 4 million RMB (31 2020 1,11 million RMB), 2 million RMB (31 2020 2 million RMB), 4 million RMB (31 2020 4 million RMB) and 0,1 million RMB (31 2020 0,1 million RMB) were used for bank loans, bank credit lines and other facilities, respectively.
30 June 2021, the collateral and pledged assets were 1 million RMB, of which 1 million RMB (31 2020 1 million RMB) were used for bank loans, bank credit lines and other facilities, respectively.

Cash Flow

Our cash flow from operations is primarily generated from the sale of our products. Cash flow from operations is affected by changes in working capital, including accounts receivable, inventory, and accounts payable. Cash flow from operations is also affected by changes in the fair value of our investments and by the sale of property, plant, and equipment. Cash flow from operations is also affected by changes in the fair value of our investments and by the sale of property, plant, and equipment. Cash flow from operations is also affected by changes in the fair value of our investments and by the sale of property, plant, and equipment.

	January – June 2021	2020
Cash flow from operations	1,707	1,411
Cash flow from investing activities	(2,450)	(2,300)
Cash flow from financing activities	770	12
Change in cash and cash equivalents	27	(177)
Cash and cash equivalents at the beginning of the period	7,325	7,254
Cash and cash equivalents at the end of the period	7,248	7,077

Capital Commitments and Capital Expenditures

Our capital commitments are primarily related to the purchase of property, plant, and equipment. Our capital expenditures are primarily related to the purchase of property, plant, and equipment. Our capital commitments are primarily related to the purchase of property, plant, and equipment. Our capital expenditures are primarily related to the purchase of property, plant, and equipment.

Management

RISK MANAGEMENT

Foreign Currency Exposure

Our foreign currency exposure is primarily related to the RMB-denominated assets and liabilities of our subsidiaries operating in foreign currencies. We manage this exposure through a combination of natural hedging and financial instruments.

Interest Rate Exposure

Our interest rate exposure is primarily related to the RMB-denominated assets and liabilities of our subsidiaries. We manage this exposure through a combination of natural hedging and financial instruments.

BUSINESS REVIEW

1. Discussion and Analysis on Operations

2021, our total revenue increased by 4.1% compared with 2020, primarily due to the increase in sales of our core products. However, our operating profit decreased by 1.2% compared with 2020, primarily due to the increase in research and development expenses and the decrease in net financial income. The decrease in operating profit was primarily due to the increase in research and development expenses of 1.5% and the decrease in net financial income of 0.3%.

Our operating profit margin decreased from 20.4% in 2020 to 19.2% in 2021, primarily due to the increase in research and development expenses and the decrease in net financial income. The decrease in operating profit margin was primarily due to the increase in research and development expenses of 1.5% and the decrease in net financial income of 0.3%.

Our net income decreased by 1.2% compared with 2020, primarily due to the increase in research and development expenses and the decrease in net financial income. The decrease in net income was primarily due to the increase in research and development expenses of 1.5% and the decrease in net financial income of 0.3%.

Our net income margin decreased from 20.4% in 2020 to 19.2% in 2021, primarily due to the increase in research and development expenses and the decrease in net financial income. The decrease in net income margin was primarily due to the increase in research and development expenses of 1.5% and the decrease in net financial income of 0.3%.

Our net income margin decreased from 20.4% in 2020 to 19.2% in 2021, primarily due to the increase in research and development expenses and the decrease in net financial income. The decrease in net income margin was primarily due to the increase in research and development expenses of 1.5% and the decrease in net financial income of 0.3%.

Our net income margin decreased from 20.4% in 2020 to 19.2% in 2021, primarily due to the increase in research and development expenses and the decrease in net financial income. The decrease in net income margin was primarily due to the increase in research and development expenses of 1.5% and the decrease in net financial income of 0.3%.

	Revenue		2020		2021
	Jan – Jun 2021	Percentage of revenue (%)	2020	2020	
	Amount	Percentage of revenue (%)	Amount	Percentage of revenue (%)	Amount
By business segment					
Construction	12,179	72.16	12,172	72.12	12,179
Services ()	2,832	16.78	2,833	16.80	2,832
Other	1,843	10.92	1,843	10.93	1,843
By geographical locations					
Construction	11,680	69.20	11,684	69.20	11,680
Services	5,198	30.80	4,011	24.11	5,198

Construction revenue for the first half of 2021 was 12,179 million, an increase of 14.2% from 10,664 million in the first half of 2020. Services revenue for the first half of 2021 was 2,832 million, a decrease of 1.3% from 2,874 million in the first half of 2020. Other revenue for the first half of 2021 was 1,843 million, a decrease of 1.3% from 1,863 million in the first half of 2020.

Segment Performance Overview

Construction revenue for the first half of 2021 was 12,179 million, an increase of 14.2% from 10,664 million in the first half of 2020. Services revenue for the first half of 2021 was 2,832 million, a decrease of 1.3% from 2,874 million in the first half of 2020. Other revenue for the first half of 2021 was 1,843 million, a decrease of 1.3% from 1,863 million in the first half of 2020.

Management

... (), ... () ...
 ... (1) ...
 24 " ... 223.21%
 () ...
 2020, 32 " 20 " (2)
 ... 32.0% ...
 (3) (-1) ...
 ... 00 "
 (4) ...
 0.0%

Major therapeutic area	Jan – Jun 2021	2020*	(%)
(1, 7)	1,705	4	2
(2, 7)	1,415	1,	1 . 2
(3, 7)	2,656	1, 2	4 .30
(4, 7)	616		1 .41
(5, 7)	1,024	1,24	1
(6, 7)	577	4 2	2

1 ... 2 . %, ...
 2 ... 1 . 2%, ...
 3 ... 4 .30%, ...
 4 ... 1 .41%, ...
 5 ... 1 . %, ...

6. ... 2. %, ...

7. ...

...

...

...

...

...

* ... 2020 ... 2021, ... 2020

& ... 2020 ... 2,00 & ... 1,400 ... 240 ... 10 ... 20 ... 3

Management

2021, К ... () ...

201, н ... 4,00 ... 2%, ... 4%, ... 2- ... 2.1 ... 3%, ... 3%, ... 4- ... 1.1 ... 2 ... 4 ... 44%.

10,000-

20 ... 2021, ... 4.314 ... 0.0\$... -1 ... -1

... () ... -1 ... 1 2 2 ... () ...

... -1 ... 2021 ...

0% ...

Table 1 — Major pipeline drug projects

Type	Number	Remarks
	2	/
	30	2.
	2	3. 1
	13	4. 1
	1 ^S	3
	103	/
	20	/
	3 ^S	/
		/
	240	/

1 ...

2 ... (奕凱達) ...

Table 2 — Small molecular innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period
1	抗肿瘤	-1 [§]	肝癌	临床三期	临床三期 (批准)
2		-1 01	肝癌	临床三期	
3		-1 01	肝癌	临床三期	临床三期 (批准)
4		-1	肝癌	临床三期	
		-1	肝癌	临床三期	临床三期 (批准)
		1001	肝癌	临床三期	临床三期 (批准)
		-4	肝癌	临床三期	
§		-011	肝癌	临床三期	
		-33 [§]	肝癌	临床三期	临床三期 (批准)
10		-43	肝癌	临床三期	临床三期 (批准)
11		-0 [§]	肝癌	临床三期	
12		01001	肝癌	临床三期	
13		-20 [§]	肝癌	临床三期	
14	抗肿瘤	-11	肝癌	临床三期	
1		-20	肝癌	临床三期	
1	抗肿瘤	103	肝癌		临床三期 (批准)
1		-2	肝癌	临床三期	

Table 3 — Biopharmaceutical innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period
1	肿瘤	1-1 (10)	1-1 ()	0. / ()	()
2		1-1 (10) ()	1-1 ()	1-1 ()	()
3			1-1 ()	0. / ()	
4			1-1 ()	0. / ()	0. / ()
			1-1 ()	0. / ()	0. / ()
			1-1 ()	0. / ()	
			1-1 ()	0. / ()	
			1-1 ()	0. / ()	
			1-1 ()	0. / ()	
			1-1 ()	0. / ()	
10			1-1 ()	0. / ()	
11	1-1 (20)	1-1 ()	0. / ()	0. / ()	
12	1-22 ()	1-22 ()	0. / ()		
13	1-1 ()	1-1 ()	0. / ()		
14	1-2 ()	1-2 ()	0. / ()		
1	1-3 ()	1-3 ()	0. / ()		
1	1-3 ()	1-3 ()	0. / ()	()	
1	1-1 (0)	1-1 ()	0. / ()	()	
1 ^b	1-2 (1)	1-2 ()	0. / ()	0. / ()	
1	1-1 ()	1-1 ()	0. / ()		
20	1-1 ()	1-1 ()	0. / ()	0. / ()	

1 0. / ()

2 0. / ()

Table 4 — License-in innovative drugs

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period
1	1. 抗肿瘤药	1. 1. 1.	1. 1. 1. (-)	1. 1. 1. 1. 1. 1.
2		1. 1. 2.	1. 1. 2. (-)	1. 1. 2. 1. 1. 1.
3	2. 抗肿瘤药	2. 1. 1.	2. 1. 1. (-)	2. 1. 1. 1. 1. 1.
4		2. 1. 2.	2. 1. 2. (-)	2. 1. 2. 1. 1. 1.
	3. 抗肿瘤药	3. 1. 1.	3. 1. 1. (-)	3. 1. 1. 1. 1. 1.
		3. 1. 2.	3. 1. 2. (-)	3. 1. 2. 1. 1. 1.
	4. 抗肿瘤药	4. 1. 1.	4. 1. 1. (-)	4. 1. 1. 1. 1. 1.
		4. 1. 2.	4. 1. 2. (-)	4. 1. 2. 1. 1. 1.
	5. 抗肿瘤药	5. 1. 1.	5. 1. 1. (-)	5. 1. 1. 1. 1. 1.
		5. 1. 2.	5. 1. 2. (-)	5. 1. 2. 1. 1. 1.
	6. 抗肿瘤药	6. 1. 1.	6. 1. 1. (-)	6. 1. 1. 1. 1. 1.
		6. 1. 2.	6. 1. 2. (-)	6. 1. 2. 1. 1. 1.
9	7. 抗肿瘤药	7. 1. 1.	7. 1. 1. (-)	7. 1. 1. 1. 1. 1.
		7. 1. 2.	7. 1. 2. (-)	7. 1. 2. 1. 1. 1.
10	8. 抗肿瘤药	8. 1. 1.	8. 1. 1. (-)	8. 1. 1. 1. 1. 1.
11		8. 1. 2.	8. 1. 2. (-)	8. 1. 2. 1. 1. 1.
12	9. 抗肿瘤药	9. 1. 1.	9. 1. 1. (-)	9. 1. 1. 1. 1. 1.
13		9. 1. 2.	9. 1. 2. (-)	9. 1. 2. 1. 1. 1.

Table 5 — Biosimilars under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period
1	-	... (, 04)	() ... "	...
2		n ... (, 0)	() ... n ... "	...
3		- 2 ... (, 11)	()	n. ...
4		- 2 ... (, 12)	(), ... ()	n. ...
		- 4 ... (, 13)	()	...
		- 6 ... (, 14)	()	n. ...
		- 3 ... (, 1)	()	...
10
11		(0)		n. ...
12				n. ...
13	...	n ... (,)		n. ...
14		n ... (,)		...

Management

Table 6

Table 6 — Major drugs approved for launch during the Reporting Period

No.	Name of drugs	Classification of registration	Indications	Remarks
1	(Name of drug)	Classification	Indications	Remarks
2	(Name of drug)	Classification	Indications	Remarks
3	(Name of drug)	Classification	Indications	Remarks
4	(Name of drug)	Classification	Indications	Remarks

1
 Indic,5 Tim ((N Representsd appro 0.25-1.25) 7 10675149(Cld9 Phaz70.2288-Rend apprA (Ct70.22eUS 5fenecr drugs of)Tj -0.00rma receiv72 0 Td (5fenecr)Tj-5thC

Table 7 — Products won tenders for centralized procurement

No.	Round selected	Name of drugs	Indications	Specifications	Packaging specification (/)	Selected price (/)	Selected quantity ('000 /)
1	4+					0.4	2,13
2				10		2.5	1,00
3	n			0.2		.3	2,
4				0.1	10	1.4	4
					0.2	10	0.
				0.1	100	.02	4,2 1
	n n			40	1	1.4	4,
				0.1	30	33.	12, 00
				2	14	10.0	2,21
10				0.2	0	.03	,3 2
11				10	14	1.2	44
12	n n			40	32	1.1	, 00
13				10	10	1.1	
14			1. 2. 3. 4.	0.	30	20.40	,3 .
1				0.2	30	.00	1
1				20	0	.0	2,10
1			0.2	100	1.4	,4	
1	n n		1. 2.	0.2	30	3.0	,300
1			1. 2. 10.	0.	14	1.2.3	3 0

Management

.....

.....

.....

Management

Management Discussion and Analysis

... 2,332 ... 434 ... 14.0% ... 31% ... 4.4 ... 4.1% ... 2020. 2021, ... 14.2% ... 24.3% ... 34.2% ... 2021, 42 ... 12 ... \$12 ... \$1 ...

Management

... 2021, ... 24,120 ... ,02 ... 3,13 ... 22.2 %, 2.1% 23.3% ... 2021, ... 20.2% ... 1,044 ... 2021, ... 4,10 ... 33.1 % ... 2021, ... 13,22 ... 24. %

* (深圳恒生醫院),

The Board of Directors is pleased to present this Interim Report for the period from 1 January 2021 to 30 June 2021. This report provides an overview of the company's performance, financial results, and strategic initiatives during this period.

The company has achieved significant milestones, including the successful completion of the restructuring process and the implementation of new strategic initiatives. The Board remains committed to ensuring the long-term sustainability and growth of the company.

The following sections provide a detailed overview of the company's performance and financial results:

- Financial Performance:** The company's revenue has increased by 15% compared to the same period last year. This growth is primarily driven by the successful implementation of the restructuring process and the launch of new products.
- Operational Performance:** The company has successfully completed the restructuring process, resulting in improved operational efficiency and reduced costs. This has led to a significant increase in profit margins.
- Strategic Initiatives:** The company has launched several new strategic initiatives, including the development of new products and the expansion of its market presence. These initiatives are expected to drive further growth and profitability in the coming years.

The Board of Directors is confident in the company's ability to continue its growth and success in the future. We will continue to monitor the company's performance closely and take appropriate actions to ensure its long-term sustainability and growth.

Management

Financing

During the reporting period, the Group's financing activities were as follows:

Item	2021, million RMB	2020, million RMB
Issuance of bank loans	1,111	1,322
Repayment of bank loans	(421)	(421)
Repayment of financial lease liabilities	(1,000)	(1,411)
Repayment of other financial liabilities	(2,400)	(2,300)
Repayment of interest	(0)	(12)
Change in cash and cash equivalents	(2,700)	(2,822)

The Group's financing activities resulted in a net decrease in cash and cash equivalents of 2,700 million RMB in 2021, compared to a net decrease of 2,822 million RMB in 2020.

2. Major Operations in the Reporting Period

A. Analysis on Principal Operations

(1)

Items	Amount for the period	Amount for the corresponding period of last year	Period-on-period change (%)
Operating income	1,111	13,211	20.4
Operating expenses	4,300	3,311	10.4
Operating profit	1,000	1,322	13.4
Other income & expenses	1,200	1,204	2.3
Profit before tax	421	421	1.4
Income tax expense	1,000	1,411	1.0
Net profit	2,400	2,300	2.1
Net profit attributable to shareholders	0	12	0.4

1. Operating income: The increase in operating income is mainly due to the increase in sales volume and price realization.

2. Operating expenses: The increase in operating expenses is mainly due to the increase in sales and administrative expenses.

3. Profit before tax: The increase in profit before tax is mainly due to the increase in operating profit and other income.

(2) &

&

&							1, 2
&							3 2
&							1, 4
&			(%)				11. 3
&							14. 1
&			(%)				20.0

1, 1.31%, 14. 1%

B. Segment and Regional Operations

(1)

Principal operations by segments

By segments	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
n	12,1	,10	,0	22.3	3 .04	. 4.21
n	2,32	1,40	4 . 4	.31	13.0	. 2.
n	1,43	1, 11	1,01	3 . 1	33. 2	. 1.1

Principal operations by products

By products	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
1. Chemical products	1,033.3	333.3	67.4	2.1	20.4	3.4
2. Biological products	1,411.1	233.3	83.4	1.2	1.0	4.2
3. Medical devices	2,111.1	1,111.1	47.2	4.30	1.4	2.9
4. Others	1,111.1	43.3	96.1	1.41	10.42	0.2
Total	5,777.6	1,523.0	73.9	1.1	24.3	20.01

Principal operations by geographical locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
1. China	11,110.0	2,111.1	81.0	1.0	2.22	3.1
2. Overseas	1,111.1	2,111.1	44.1	2.1	32.3	2.13
Total	12,221.1	4,222.2	65.9	1.1	24.3	20.01

C. Subsidiaries and Investees
(1)

Company name	Nature of business	Major products or services	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
...	1	,12	4,20	2, 1	430	3 ⁵
...	4 2	,4 3	3,044	3,343	34	31 ⁵
...	/	1,4	,102	1,03	1 ⁵	4 1

Company name	Nature of business	Major products	Registered capital	Total assets	Net assets	Revenue	Net profit
...	10	2, 2	2,02	14	4
...	43	, 30	2, 1	34	3 4
...	0	3,0 ⁵ 0	1, 3	00	103
...	/	2, 44	2,223	11	112

Management

2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0

(2)

10%

Company name	Nature of business	Principal activities	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
0	0	0	100	344,244	4,000	24,120	,4	,033

(3)

2020,	0	0	0	0	0	0	0	0
100%	0	0	0	0	0	0	0	0
(0	0	0	0	0	0	0	0
,	0	0	0	0	0	0	0	0
100%	0	0	0	0	0	0	0	0
2021,	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
(0	0	0	0	0	0	0	0
)* (0	0	0	0	0	0	0	0
)* (0	0	0	0	0	0	0	0
)* (0	0	0	0	0	0	0	0
0%	0	0	0	0	0	0	0	0
0%	0	0	0	0	0	0	0	0

Name of subsidiary	Acquired through	Net assets (as at the end of the Reporting Period)	Net profit (from date of merger/ acquisition up to the end of the Reporting Period)	Date of acquisition/ merger
JSC "Yuzhneye Sibirskie Avtomobilnye Mashinostroyeniye" (YSMA)	acquisition of 100% of shares	31	1	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Alma-Art"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021
JSC "Kumyshtal"	acquisition of 100% of shares	1	-	01.11.2021

E. Employees and Remuneration Policies

於 2021 年 6 月 30 日，本公司共有 34,300 名員工。本公司根據員工的職位、表現及經驗釐定其薪酬政策。本公司亦設有長期激勵計劃，以吸引及挽留人才。

3. Outlook for Operations in the Second Half of 2021

A. Competition and Development Trends of the Industry

於 2021 年 6 月 30 日，中國製藥行業正處於快速發展階段。隨著人口老齡化及居民健康意識提高，藥品需求持續增長。同時，政府加強了對藥品研發及生產的監管，推動行業向高質量、高附加值方向發展。此外，數字化技術在製藥行業的應用日益廣泛，為提高生產效率及降低成本提供了有力支持。

本公司將繼續加大研發投入，加強與國際知名藥企的合作，提升產品競爭力。同時，我們將進一步優化生產工藝，提高生產效率，以應對日益激烈的市場競爭。

於 2021 年 6 月 30 日，全球製藥行業面臨著諸多挑戰。受 COVID-19 疫情影響，全球經濟增長放緩，藥品需求受到一定程度的抑制。然而，隨著疫苗研發的進展及治療方案的不斷完善，全球製藥行業正逐步恢復正常發展軌道。同時，全球各國政府加強了對藥品價格的管控，對藥企的盈利空間造成了一定壓力。

本公司將密切關注全球製藥行業的發展動態，及時調整經營策略。我們將進一步加強與全球領先藥企的合作，引進先進技術及人才，提升產品研發水平。同時，我們將積極參與國際市場競爭，擴大產品銷售渠道，提高品牌影響力。

本公司將繼續秉承「以人為本、科技創新」的經營理念，不斷加大研發投入，提升產品質量及競爭力。同時，我們將進一步加強與國際知名藥企的合作，引進先進技術及人才，提升產品研發水平。此外，我們將積極參與社會公益事業，履行企業社會責任，為社會做出積極貢獻。

於 2021 年 6 月 30 日，本公司共有 34,300 名員工。本公司根據員工的職位、表現及經驗釐定其薪酬政策。本公司亦設有長期激勵計劃，以吸引及挽留人才。

* (蘇州開拓藥業股份有限公司)

Management

Management Discussion and Analysis

2021, the Company's operating performance is as follows:

2021, the Company's operating performance is as follows:

2021, the Company's operating performance is as follows:

2021, the Company's operating performance is as follows:

התאגדותנו מתמקדת במתן פתרונות דיגיטליים ללקוחותינו, ופיתוח מוצרים חדשים המבוססים על טכנולוגיית המגוון. במהלך השנה האחרונה, התאגדותנו המשיכה להשקיע משאבים רבים בפיתוח מוצרים חדשים, ובשיתוף פעולה עם לקוחותינו. הפיתוחים האלו יאפשרו לנו להציע ללקוחותינו פתרונות דיגיטליים חדשים, המבוססים על טכנולוגיית המגוון, ויסייעו לנו להשיג את מטרותינו האסטרטגיות.

במהלך השנה האחרונה, התאגדותנו המשיכה להשקיע משאבים רבים בפיתוח מוצרים חדשים, ובשיתוף פעולה עם לקוחותינו. הפיתוחים האלו יאפשרו לנו להציע ללקוחותינו פתרונות דיגיטליים חדשים, המבוססים על טכנולוגיית המגוון, ויסייעו לנו להשיג את מטרותינו האסטרטגיות. הפיתוחים האלו יאפשרו לנו להציע ללקוחותינו פתרונות דיגיטליים חדשים, המבוססים על טכנולוגיית המגוון, ויסייעו לנו להשיג את מטרותינו האסטרטגיות.

התאגדותנו מתמקדת במתן פתרונות דיגיטליים ללקוחותינו, ופיתוח מוצרים חדשים המבוססים על טכנולוגיית המגוון. במהלך השנה האחרונה, התאגדותנו המשיכה להשקיע משאבים רבים בפיתוח מוצרים חדשים, ובשיתוף פעולה עם לקוחותינו. הפיתוחים האלו יאפשרו לנו להציע ללקוחותינו פתרונות דיגיטליים חדשים, המבוססים על טכנולוגיית המגוון, ויסייעו לנו להשיג את מטרותינו האסטרטגיות.

במהלך השנה האחרונה, התאגדותנו המשיכה להשקיע משאבים רבים בפיתוח מוצרים חדשים, ובשיתוף פעולה עם לקוחותינו. הפיתוחים האלו יאפשרו לנו להציע ללקוחותינו פתרונות דיגיטליים חדשים, המבוססים על טכנולוגיית המגוון, ויסייעו לנו להשיג את מטרותינו האסטרטגיות.

התאגדותנו מתמקדת במתן פתרונות דיגיטליים ללקוחותינו, ופיתוח מוצרים חדשים המבוססים על טכנולוגיית המגוון. במהלך השנה האחרונה, התאגדותנו המשיכה להשקיע משאבים רבים בפיתוח מוצרים חדשים, ובשיתוף פעולה עם לקוחותינו. הפיתוחים האלו יאפשרו לנו להציע ללקוחותינו פתרונות דיגיטליים חדשים, המבוססים על טכנולוגיית המגוון, ויסייעו לנו להשיג את מטרותינו האסטרטגיות.

Management

4. Potential Risks

A. Risks in relation to industry policies and system reforms

The pharmaceutical industry in China is undergoing significant changes due to government policies and system reforms. The government has implemented a series of measures to reduce the burden of medical expenses on patients, including the implementation of a comprehensive medical insurance system and the reform of the drug pricing mechanism. These measures have led to a decline in the average price of drugs, which has had a negative impact on the profitability of pharmaceutical companies. In addition, the government has also implemented a series of measures to encourage innovation in the pharmaceutical industry, including the implementation of a new drug approval system and the reform of the clinical trial system. These measures have led to an increase in the number of new drugs being developed and approved, which is expected to have a positive impact on the long-term development of the pharmaceutical industry.

... (1) ... (2) ... (3) ... (4) ... (5) ... (6) ... (7) ... (8) ... (9) ... (10) ... (11) ... (12) ... (13) ... (14) ... (15) ... (16) ... (17) ... (18) ... (19) ... (20) ... (21) ... (22) ... (23) ... (24) ... (25) ... (26) ... (27) ... (28) ... (29) ... (30) ... (31) ... (32) ... (33) ... (34) ... (35) ... (36) ... (37) ... (38) ... (39) ... (40) ... (41) ... (42) ... (43) ... (44) ... (45) ... (46) ... (47) ... (48) ... (49) ... (50) ... (51) ... (52) ... (53) ... (54) ... (55) ... (56) ... (57) ... (58) ... (59) ... (60) ... (61) ... (62) ... (63) ... (64) ... (65) ... (66) ... (67) ... (68) ... (69) ... (70) ... (71) ... (72) ... (73) ... (74) ... (75) ... (76) ... (77) ... (78) ... (79) ... (80) ... (81) ... (82) ... (83) ... (84) ... (85) ... (86) ... (87) ... (88) ... (89) ... (90) ... (91) ... (92) ... (93) ... (94) ... (95) ... (96) ... (97) ... (98) ... (99) ... (100) ...

... (101) ... (102) ... (103) ... (104) ... (105) ... (106) ... (107) ... (108) ... (109) ... (110) ... (111) ... (112) ... (113) ... (114) ... (115) ... (116) ... (117) ... (118) ... (119) ... (120) ... (121) ... (122) ... (123) ... (124) ... (125) ... (126) ... (127) ... (128) ... (129) ... (130) ... (131) ... (132) ... (133) ... (134) ... (135) ... (136) ... (137) ... (138) ... (139) ... (140) ... (141) ... (142) ... (143) ... (144) ... (145) ... (146) ... (147) ... (148) ... (149) ... (150) ...

... (151) ... (152) ... (153) ... (154) ... (155) ... (156) ... (157) ... (158) ... (159) ... (160) ... (161) ... (162) ... (163) ... (164) ... (165) ... (166) ... (167) ... (168) ... (169) ... (170) ... (171) ... (172) ... (173) ... (174) ... (175) ... (176) ... (177) ... (178) ... (179) ... (180) ... (181) ... (182) ... (183) ... (184) ... (185) ... (186) ... (187) ... (188) ... (189) ... (190) ... (191) ... (192) ... (193) ... (194) ... (195) ... (196) ... (197) ... (198) ... (199) ... (200) ...

C. Business and operating risks

(1) &

... (201) ... (202) ... (203) ... (204) ... (205) ... (206) ... (207) ... (208) ... (209) ... (210) ... (211) ... (212) ... (213) ... (214) ... (215) ... (216) ... (217) ... (218) ... (219) ... (220) ... (221) ... (222) ... (223) ... (224) ... (225) ... (226) ... (227) ... (228) ... (229) ... (230) ... (231) ... (232) ... (233) ... (234) ... (235) ... (236) ... (237) ... (238) ... (239) ... (240) ... (241) ... (242) ... (243) ... (244) ... (245) ... (246) ... (247) ... (248) ... (249) ... (250) ...

... (251) ... (252) ... (253) ... (254) ... (255) ... (256) ... (257) ... (258) ... (259) ... (260) ... (261) ... (262) ... (263) ... (264) ... (265) ... (266) ... (267) ... (268) ... (269) ... (270) ... (271) ... (272) ... (273) ... (274) ... (275) ... (276) ... (277) ... (278) ... (279) ... (280) ... (281) ... (282) ... (283) ... (284) ... (285) ... (286) ... (287) ... (288) ... (289) ... (290) ... (291) ... (292) ... (293) ... (294) ... (295) ... (296) ... (297) ... (298) ... (299) ... (300) ...

Management

.....

(2)

.....

.....

.....

(3)

.....

.....

D. Management risks

(1)

Management risks are risks that are directly related to the business operations of the Group. Management risks include risks related to the Group's business strategy, risks related to the Group's financial position, risks related to the Group's human resources, risks related to the Group's information technology, risks related to the Group's legal and regulatory environment, risks related to the Group's reputation, risks related to the Group's environmental and social performance, risks related to the Group's cybersecurity, risks related to the Group's supply chain, risks related to the Group's customer relationships, risks related to the Group's product development, risks related to the Group's sales and marketing, risks related to the Group's operations, risks related to the Group's compliance, risks related to the Group's talent management, risks related to the Group's innovation, risks related to the Group's sustainability, risks related to the Group's risk management, risks related to the Group's governance, risks related to the Group's internal control, risks related to the Group's data privacy, risks related to the Group's intellectual property, risks related to the Group's cybersecurity, risks related to the Group's supply chain, risks related to the Group's customer relationships, risks related to the Group's product development, risks related to the Group's sales and marketing, risks related to the Group's operations, risks related to the Group's compliance, risks related to the Group's talent management, risks related to the Group's innovation, risks related to the Group's sustainability, risks related to the Group's risk management, risks related to the Group's governance, risks related to the Group's internal control, risks related to the Group's data privacy, risks related to the Group's intellectual property.

(2)

Management risks are risks that are directly related to the business operations of the Group. Management risks include risks related to the Group's business strategy, risks related to the Group's financial position, risks related to the Group's human resources, risks related to the Group's information technology, risks related to the Group's legal and regulatory environment, risks related to the Group's reputation, risks related to the Group's environmental and social performance, risks related to the Group's cybersecurity, risks related to the Group's supply chain, risks related to the Group's customer relationships, risks related to the Group's product development, risks related to the Group's sales and marketing, risks related to the Group's operations, risks related to the Group's compliance, risks related to the Group's talent management, risks related to the Group's innovation, risks related to the Group's sustainability, risks related to the Group's risk management, risks related to the Group's governance, risks related to the Group's internal control, risks related to the Group's data privacy, risks related to the Group's intellectual property.

E. Foreign exchange risk

Foreign exchange risk is the risk that the value of the Group's assets, liabilities, or cash flows will fluctuate due to changes in the exchange rate of the Group's functional currency against the currencies of the countries in which the Group operates. The Group's functional currency is the Hong Kong dollar. The Group's assets, liabilities, and cash flows are denominated in various currencies, including the Hong Kong dollar, the Chinese renminbi, and the United States dollar. The Group is exposed to foreign exchange risk primarily through its sales and purchases in foreign currencies. The Group's management monitors foreign exchange risk and uses various strategies to manage the risk, including natural hedging and the use of financial derivatives.

F. Force majeure risks

Force majeure risks are risks that are caused by events that are beyond the control of the Group, such as natural disasters, wars, and pandemics. The Group's management monitors force majeure risks and uses various strategies to manage the risk, including the purchase of insurance and the implementation of business continuity plans.

5. Other Events

A. Shareholding Increase Plan of the Controlling Shareholder

2020

The Controlling Shareholder has announced a shareholding increase plan for 2020. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2020. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2020. The Controlling Shareholder has also announced a shareholding increase plan for 2021. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2021. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2021. The Controlling Shareholder has also announced a shareholding increase plan for 2022. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2022. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2022. The Controlling Shareholder has also announced a shareholding increase plan for 2023. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2023. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2023. The Controlling Shareholder has also announced a shareholding increase plan for 2024. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2024. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2024. The Controlling Shareholder has also announced a shareholding increase plan for 2025. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2025. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2025. The Controlling Shareholder has also announced a shareholding increase plan for 2026. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2026. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2026. The Controlling Shareholder has also announced a shareholding increase plan for 2027. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2027. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2027. The Controlling Shareholder has also announced a shareholding increase plan for 2028. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2028. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2028. The Controlling Shareholder has also announced a shareholding increase plan for 2029. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2029. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2029. The Controlling Shareholder has also announced a shareholding increase plan for 2030. The plan is to increase the Controlling Shareholder's shareholding in the Group to 100% by the end of 2030. The Controlling Shareholder has already increased its shareholding from 99.99% to 100% in 2030.

Management

B. The Mandate to Issue Inter-bank Market Debt Financing Instruments

On 2021, the Company obtained the mandate to issue inter-bank market debt financing instruments with a total amount of RMB 1.2 billion. The interest rate of the debt financing instruments is 3.10%.

On 2021, the Company obtained the mandate to issue inter-bank market debt financing instruments with a total amount of RMB 1.2 billion. The interest rate of the debt financing instruments is 2.0%.

C. The Public Issuance of Corporate Bonds to Qualified Investors

On 2021, the Company obtained the mandate to issue corporate bonds to qualified investors with a total amount of RMB 1.2 billion. The interest rate of the corporate bonds is 3.1%.

D. Proposed non-public issuance of A shares

On 2020, the Company proposed a non-public issuance of A shares with a total amount of RMB 1.2 billion. The Company has obtained the administrative permit to accept applications (《中國證監會行政許可申請受理單》) for the non-public issuance of A shares with a total amount of RMB 1.2 billion (RMB 2100 million).

On 2021, the Company proposed a non-public issuance of A shares with a total amount of RMB 4,433 million (RMB 4,433 million).

On 2021, the Company proposed a non-public issuance of A shares with a total amount of RMB 12,144,200 (RMB 12,144,200).

E. 2021 Restricted Share Incentive Scheme

On 2021, the Company proposed a restricted share incentive scheme with a total amount of RMB 11 million.

On 2021, the Company proposed a restricted share incentive scheme with a total amount of RMB 11 million.

RESULTS AND DIVIDENDS

	30 June 2021	30 June 2020
Profit attributable to equity holders of the parent	1,000,000	1,000,000
Dividend per share	0.00	0.00

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

	30 June 2021	30 June 2020
Number of securities purchased, sold or redeemed	0	0
Amount paid or received	0	0

DIRECTORS

The following table sets out the names of the directors of the Company during the period from 1 January 2021 to 30 June 2021.

Executive Director

Ms. Wu Yifang (吳以芳) (Executive Director)

Non-executive Directors

- Mr. Chen Qiyu (陳啟宇)
- Ms. Yao Fang (姚方)
- Mr. Xu Xiaoliang (徐曉亮)
- Mr. Gao Ping (龔平)
- Mr. Pan Donghui (潘東輝)
- Mr. Zhang Houlin (張厚林)

Independent Non-executive Directors

- Ms. Li Ling (李玲)
- Mr. Tang Yuliang (湯谷良)
- Mr. Wang Quanyang (王全弟)
- Mr. Yu Zishan (余梓山)

	11 June 2021	11 June 2020
Number of securities purchased, sold or redeemed	0	0
Amount paid or received	0	0

Statutory

SUPERVISORS

任倩 (Ren Qian) (任倩) (曹根興) (Cao Genxing) (管一民) (Guan Yimin)

CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

2021年10月10日

北京三元食品股份有限公司 (Beijing Sanyuan Food Co., Ltd.) (0042)

上海百聯集團股份有限公司 (Shanghai Bailian Group Co., Ltd.) (0052)

2021年11月11日

2021年11月30日

2021年13月12日

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

2021年2月2日

1,044 1.1%

Statutory

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2021, the interests and short positions of the Directors, Supervisors and Chief Executive in the Shares, underlying Shares and debentures of the Company are as follows:

(1) Long positions in the Shares, underlying Shares and debentures of the Company

Name of Directors/ chief executive	Capacity	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
Mr. Zhang Zhong	Director	Ordinary Shares	342,000 ()	0.0 %
Mr. Zhang Zhong	Director	Ordinary Shares	1,000 ()	0.04%
Mr. Zhang Zhong	Director	Ordinary Shares	114,000 ()	0.01%
Mr. Zhang Zhong	Director	Ordinary Shares	4,330 ()	0.02%

(1) () represents 10,000 shares.

(2) Long positions in the shares, underlying shares and debentures of the Company's associated corporations (within the meaning of Part XV of the SFO)

Name of Directors/ chief executive	Name of associated corporation	Class of Shares	Capacity	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	22,000 () ⁽²⁾	0.2 %
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	1,400 ()	0.00%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	40,000 () ⁽³⁾	0.01%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	20,000 () ⁽⁴⁾	0.24%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	2,320 ()	0.00%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	11,200,000 () ⁽¹⁾	0.13%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	1,000 ()	0.00%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	11,100,000 () ⁽¹⁾	0.13%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	11,100,000 () ⁽¹⁾	0.13%

(1) () represents 10,000 shares.

(2) 31 June 2021, 1,200,000 shares, 1,000,000 shares.

(3) 31 June 2021, 240,000 shares, 400,000 shares.

(4) 31 June 2021, 1,200,000 shares, 1,000,000 shares.

() 31 June 2021, 40,000 shares, 1,000,000 shares.

() 31 June 2021, 0,000 shares, 1,000,000 shares.

() 31 June 2021, 0,000 shares, 1,000,000 shares.

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

As at 30 June 2021, the interests and short positions of substantial shareholders in the shares and underlying shares of the Company are as follows:

Name of Shareholders	Nature of interest	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
Mr. Chan Siu-ming	Beneficial	Ordinary	1,333,000	12.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	3,020,000	4.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	1,000,000	1.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	1,333,000	12.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	3,020,000	4.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	1,333,000	14.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	3,020,000	4.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	1,333,000	14.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	3,020,000	4.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	1,333,000	14.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	3,020,000	4.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	114,000	0.01%
Mr. Chan Siu-ming	Beneficial	Ordinary	2,115,000	2.2%
Mr. Chan Siu-ming	Beneficial	Ordinary	1,220,000	0.23%
Mr. Chan Siu-ming	Beneficial	Ordinary	1,115,000	1.0%
Mr. Chan Siu-ming	Beneficial	Ordinary	43,000	1.02%
Mr. Chan Siu-ming	Beneficial	Ordinary	22,040,000	3.0%

(1) (€) represents (€) million.

(2) Mr. Chan Siu-ming owns 1,333,000 shares, representing 12.0% of the issued share capital of 11,100,000 shares of the Company, and 3,020,000 shares, representing 2.14% of the issued share capital of 141,000,000 shares of the Company. Mr. Chan Siu-ming also holds 1,000,000 shares of the Company, representing 0.2% of the issued share capital of 50,000,000 shares of the Company.

(3) Mr. Chan Siu-ming holds 1,333,000 shares, representing 12.0% of the issued share capital of 11,100,000 shares of the Company, and 3,020,000 shares, representing 2.14% of the issued share capital of 141,000,000 shares of the Company. Mr. Chan Siu-ming also holds 1,000,000 shares of the Company, representing 0.2% of the issued share capital of 50,000,000 shares of the Company.

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

None of the directors or supervisors of the Company has any right to acquire shares or debentures of the Company.

Statutory

MODEL CODE FOR SECURITIES TRANSACTIONS

Our Board of Directors has adopted the Model Code for Securities Transactions, which is designed to ensure that all directors, officers and employees of the Company are aware of the standards of conduct expected of them in relation to the Company's securities. The Model Code is available on the Company's website at www.fosunpharm.com.

COMPLIANCE WITH THE CG CODE

The Company has adopted the CG Code as its code of conduct. The CG Code is available on the Company's website at www.fosunpharm.com. The Company is committed to ensuring that all directors, officers and employees are aware of the standards of conduct expected of them in relation to the Company's securities.

The Company has also adopted the Model Code for Securities Transactions, which is designed to ensure that all directors, officers and employees of the Company are aware of the standards of conduct expected of them in relation to the Company's securities. The Model Code is available on the Company's website at www.fosunpharm.com.

The Company has adopted the Model Code for Securities Transactions, which is designed to ensure that all directors, officers and employees of the Company are aware of the standards of conduct expected of them in relation to the Company's securities. The Model Code is available on the Company's website at www.fosunpharm.com.

2.1 The Company has adopted the Model Code for Securities Transactions, which is designed to ensure that all directors, officers and employees of the Company are aware of the standards of conduct expected of them in relation to the Company's securities. The Model Code is available on the Company's website at www.fosunpharm.com.

2020, the Company has adopted the Model Code for Securities Transactions, which is designed to ensure that all directors, officers and employees of the Company are aware of the standards of conduct expected of them in relation to the Company's securities. The Model Code is available on the Company's website at www.fosunpharm.com.

2004, the Company has adopted the Model Code for Securities Transactions, which is designed to ensure that all directors, officers and employees of the Company are aware of the standards of conduct expected of them in relation to the Company's securities. The Model Code is available on the Company's website at www.fosunpharm.com.

2.1, the Company has adopted the Model Code for Securities Transactions, which is designed to ensure that all directors, officers and employees of the Company are aware of the standards of conduct expected of them in relation to the Company's securities. The Model Code is available on the Company's website at www.fosunpharm.com.

The Company has adopted the Model Code for Securities Transactions, which is designed to ensure that all directors, officers and employees of the Company are aware of the standards of conduct expected of them in relation to the Company's securities. The Model Code is available on the Company's website at www.fosunpharm.com.

()

2.1

REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

11 2021, ...

Interim Condensed Consolidated

Interim Condensed Consolidated Financial Statements

30 June 2021

		For the six months ended	
		2021	2020
		RMB'000	'000
		(Unaudited)	(Unaudited)
REVENUE		16,877,537	13,001,100
Revenue from operations		(8,110,878)	(8,214,822)
Other income		8,766,659	11,430,300
Finance income		141,714	1,042,000
Finance costs		(4,356,975)	(3,310,000)
Share of profit of associates		(1,505,057)	(1,322,230)
Share of profit of joint ventures		(1,561,885)	(1,204,420)
Other income		(14,804)	(42,000)
Other income		1,645,255	1,032,200
Other income		(338,367)	(2,138,000)
Other income		116,605	43,000
Other income		(420,725)	(424,000)
Other income		(93,817)	(4,000)
Other income		925,626	1,100,400
PROFIT BEFORE TAX		3,304,229	2,301,100
Income tax expense	10	(550,647)	(3,208,100)
PROFIT FOR THE PERIOD		2,753,582	1,093,000
Profit for the period attributable to ordinary equity holders of the parent		2,482,373	1,141,000
Profit for the period attributable to non-controlling interests		271,209	(48,000)
PROFIT FOR THE PERIOD		2,753,582	1,093,000
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	12		
Basic earnings per share		RMB0.97 Yuan	0.40 Yuan
Diluted earnings per share		RMB0.97 Yuan	0.40 Yuan

Interim Condensed Consolidated

Income Statement

For the interim period ended 30 June 2021

Interim Condensed Consolidated

30 2021

		30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
NON-CURRENT ASSETS			
	13	11,986,909	12, 3
		2,574,667	2, ,402
		8,622,217	1, ,24
		9,730,364	, ,41
		349,077	3 1, 1
		22,447,860	21 0,
		6,243	1,043
		1,459,128	1,4 0,
		232,984	244, 3
		1,807,055	1,0 3, 24
		59,216,504	1, 44,320
CURRENT ASSETS			
	14	5,485,618	,1 2 00
		6,028,237	4 0, 0
		3,462,140	2, 4,1
		3,267,854	1, 0,0
		472,998	2 1 1
		10,489,133	, 1 02
		29,205,980	2 ,0 4 03
CURRENT LIABILITIES			
	1	3,745,584	3,2 0,21
		6,582,248	, , 4
	1	15,852,411	14,4 1, 4
		140,052	1 1,0 4
		1,447,288	1,020,30
		389,670	32 ,42
		28,157,253	24 2,3 3
NET CURRENT ASSETS		1,048,727	212,4 0
TOTAL ASSETS LESS CURRENT LIABILITIES		60,265,231	1, , 0

Interim Condensed Consolidated

30 June 2021

		30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
NON-CURRENT LIABILITIES			
Long-term debt	1	8,513,509	1,400,000
Other non-current liabilities		706,945	2,201
Provisions		2,935,378	2,201
Deferred tax liabilities		506,250	4,220
Other non-current liabilities		277,854	2,400
		285,708	121,120
		13,225,644	12,225,644
Net assets		47,039,587	4,203,300
EQUITY			
Equity attributable to owners of the parent		2,562,899	2,201
Reserves		35,241,150	34,300,000
		37,804,049	3,300,000
Non-controlling interests		9,235,538	1,111,400
Total equity		47,039,587	4,203,300

Interim Condensed Consolidated

30 2021

	Attributable to owners of the parent									
	Share capital RMB'000	Share premium RMB'000	Fair value reserve RMB'000	Statutory surplus reserve RMB'000	Other reserve RMB'000	Exchange fluctuation reserve RMB'000	Retained profits RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
1 2021 ()	2,562,899	11,385,162*	139,710*	2,728,604*	3,888,329*	(1,061,719)*	17,295,662*	36,938,647	8,988,749	45,927,396
	—	—	—	—	—	—	2,482,373	2,482,373	271,209	2,753,582
	—	—	2,698	—	—	—	—	2,698	1,722	4,420
	—	—	64,833	—	—	—	—	64,833	—	64,833
	—	—	—	—	—	(164,832)	—	(164,832)	(36,880)	(201,712)
	—	—	67,531	—	—	(164,832)	2,482,373	2,385,072	236,051	2,621,123
	—	—	—	—	(460,551)	—	—	(460,551)	(67,129)	(527,680)
	—	—	—	—	—	—	—	—	9,600	9,600
	—	—	—	—	—	—	—	—	169,710	169,710
	—	—	—	—	9,104	—	—	9,104	37,128	46,232
	—	—	—	—	(17,557)	—	—	(17,557)	—	(17,557)
	—	—	—	—	—	—	—	—	35,420	35,420
	—	—	—	—	—	—	—	—	(65,723)	(65,723)
	—	—	—	(2,449)	—	—	2,449	—	(175,821)	(175,821)
	—	—	—	—	—	—	—	—	58,179	58,179
	—	—	—	—	6,469	—	—	6,469	(4,166)	2,303
	—	—	—	—	45,862	—	—	45,862	13,540	59,402
2020 ()	—	—	—	—	—	—	(1,102,997)	(1,102,997)	—	(1,102,997)
30 2021 ()	2,562,899	11,385,162*	207,241*	2,726,155*	3,471,656*	(1,226,551)*	18,677,487*	37,804,049	9,235,538	47,039,587

* The amounts are subject to audit by the independent member of the audit firm. The amounts are subject to audit by the independent member of the audit firm. The amounts are subject to audit by the independent member of the audit firm.

Interim Condensed Consolidated

Financial statements ended 30 June 2021

	Interim Condensed Consolidated Financial Statements									
	30 June 2021		30 June 2020		31 December 2020		31 December 2019		31 December 2018	
	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000
1. Revenue	2,228	11,351	2*	(3,4)*	2,238	1,338	(420)	14,133	31,311	31,143
Cost of sales								1,140	1,140	1,458
Profit before tax										
Income tax expense										
Profit after tax										
Other income										
Other expenses										
Net profit										
Profit before tax										
Income tax expense										
Profit after tax										
Other income										
Other expenses										
Net profit										
Profit before tax										
Income tax expense										
Profit after tax										
Other income										
Other expenses										
Net profit										
Profit before tax										
Income tax expense										
Profit after tax										
Other income										
Other expenses										
Net profit										
Profit before tax										
Income tax expense										
Profit after tax										
Other income										
Other expenses										
Net profit										
Profit before tax										
Income tax expense										
Profit after tax										
Other income										
Other expenses										
Net profit										
Profit before tax										
Income tax expense										
Profit after tax										
Other income										
Other expenses										
Net profit										
Profit before tax										
Income tax expense										
Profit after tax										
Other income										
Other expenses										
Net profit										
Profit before tax										
Income tax expense										
Profit after tax										
Other income										
Other expenses										
Net profit										

* The figures for the period from 1 January to 30 June 2021 are based on the consolidated financial statements for the period from 1 January to 30 June 2021. The figures for the period from 1 January to 31 December 2020 are based on the consolidated financial statements for the period from 1 January to 31 December 2020. The figures for the period from 1 January to 31 December 2019 are based on the consolidated financial statements for the period from 1 January to 31 December 2019. The figures for the period from 1 January to 31 December 2018 are based on the consolidated financial statements for the period from 1 January to 31 December 2018.

Interim Condensed Consolidated

Interim Condensed Consolidated Financial Statements

		For the six months ended 30 June	
		2021	2020
		RMB'000	'000
		(Unaudited)	(Unaudited)
Operating profit		2,094,337	1,222,222
Finance income		(387,696)	(4,325)
Finance expense			
Profit before income tax		1,706,641	1,217,897
Income tax expense			
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisition of subsidiaries		(2,286,070)	(1,041,145)
Acquisition of intangible assets	1	(21,391)	(5,400)
Acquisition of property, plant and equipment		(100,172)	(1,243,100)
Acquisition of financial assets at fair value through profit or loss		(191,752)	(43,000)
Disposal of property, plant and equipment		537,242	1,100,000
Disposal of financial assets at fair value through profit or loss		80,764	4,444
Disposal of subsidiaries	1	237,609	
Disposal of intangible assets		61,154	1,000
Disposal of financial assets at fair value through profit or loss		8,009	1,000
Disposal of property, plant and equipment		—	1,000
Disposal of financial assets at fair value through profit or loss		18,421	43
(Increase)/decrease in cash held		(12,392)	3,400
Change in cash held		—	0,225
Change in cash held		(819,125)	(819,125)
Change in cash held		37,959	(42,333)
Change in cash held		(2,449,744)	(2,311,333)

Interim Condensed Consolidated

Financial Statement
For the interim period ended 30 June 2021

	For the six months ended	
	2021	2020
	RMB'000	'000
	(Unaudited)	(Unaudited)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from the issuance of shares	14,330,459	1,141,411
Proceeds from the issuance of debt	(12,723,895)	(4,311,311)
Proceeds from the issuance of convertible preferred shares	(419,549)	(441,311)
Proceeds from the issuance of convertible preferred shares	(68,914)	(1,431)
Proceeds from the issuance of convertible preferred shares	251,362	1,231
Proceeds from the issuance of convertible preferred shares	—	(2,241)
Proceeds from the issuance of convertible preferred shares	(69,024)	(1,411,311)
Proceeds from the issuance of convertible preferred shares	(530,770)	(1,111)
	769,669	1,203,111
Proceeds from the issuance of convertible preferred shares	26,566	(1,331)
Proceeds from the issuance of convertible preferred shares	7,324,881	1,243,111
Proceeds from the issuance of convertible preferred shares	(103,270)	(1,431)
	7,248,177	1,111,411
Analysis of balances of cash and cash equivalents:		
Balance at the beginning of the period	10,489,133	1,041,111
Change in cash and cash equivalents	(3,240,956)	(1,341,111)
Balance at the end of the period	7,248,177	1,111,411

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

()

κ 3, κ 4 κ 1

2

24

30 2021

30 2022

1 2021

30 2021

30 2022

30,000

30 2021

4. OPERATING SEGMENT INFORMATION

本公司按照《企业会计准则》的规定披露分部信息，分部信息以内部报告为基础确定。分部信息以业务类型为基础确定，主要业务类型包括：

- () 化学原料药及制剂
- () 化学制剂
- () 化学原料药及制剂
- () 化学原料药及制剂
- () 化学原料药及制剂
- () 化学原料药及制剂

本公司按照《企业会计准则》的规定披露分部信息，分部信息以内部报告为基础确定。分部信息以业务类型为基础确定，主要业务类型包括：

- () 化学原料药及制剂
- () 化学制剂
- () 化学原料药及制剂
- () 化学原料药及制剂
- () 化学原料药及制剂
- () 化学原料药及制剂

本公司按照《企业会计准则》的规定披露分部信息，分部信息以内部报告为基础确定。分部信息以业务类型为基础确定，主要业务类型包括：

Notes to Interim Condensed Consolidated

30 June 2021

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2021 (unaudited)

	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Eliminations RMB'000	Total RMB'000
Segment revenue							
Revenue from sales to customers	12,179,257	2,832,211	1,843,434	—	22,635	—	16,877,537
Revenue from sales to other segments	13,233	17,779	20,501	—	12,639	(64,152)	—
Revenue	12,192,490	2,849,990	1,863,935	—	35,274	(64,152)	16,877,537
Segment results*							
Segment profit	1,352,891	434,099	(19,393)	—	9,266	(23,352)	1,753,511
Segment expense	102,012	14,123	15,428	—	7,430	—	138,993
Segment income	201,990	2,283	87,416	—	262,270	(111,725)	442,234
Segment expense	85,180	16,516	14,508	—	1,698	(14,636)	103,266
Segment income	(80,436)	(13,698)	(25,545)	—	(5,312)	21,894	(103,097)
Segment expense	(35,582)	(34,764)	(12,181)	—	(258,830)	—	(341,357)
Segment income	(93,805)	—	—	—	(12)	—	(93,817)
Segment expense	35,707	90,143	(28,178)	896,991	(69,037)	—	925,626
Segment income	—	—	—	—	—	—	478,870
Segment expense	1,567,957	508,702	32,055	896,991	(52,527)	(127,819)	3,304,229
Segment income	(311,399)	(54,486)	(47,288)	—	(2)	—	(413,175)
Segment expense	—	—	—	—	—	—	(137,472)
Segment income	1,256,558	454,216	(15,233)	896,991	(52,529)	(127,819)	2,753,582
Segment assets:	46,659,269	8,322,272	9,898,810	15,355,639	4,458,138	(2,668,056)	82,026,072
Segment asset	342,929	—	—	—	6,148	—	349,077
Segment asset	2,273,758	555,078	1,589,874	15,355,639	2,673,511	—	22,447,860
Segment asset	—	—	—	—	—	—	6,396,412
Segment asset	—	—	—	—	—	—	88,422,484
Segment liabilities:	17,422,127	2,202,799	2,555,456	—	710,137	(10,426,621)	12,463,898
Segment liability	—	—	—	—	—	—	28,918,999
Segment liability	—	—	—	—	—	—	41,382,897
Other segment information:							
Other segment information	643,074	123,971	157,392	—	21,010	—	945,447
Other segment information	(1,288)	25,438	7,872	—	190,114	—	222,136
Other segment information**	1,323,129	137,508	477,910	—	102,565	—	2,041,112

* Segment results are presented on a cost of sales basis. The results of the segments are not necessarily comparable to the results of the corresponding segments of the Group in the previous period.

** Other segment information represents the results of the segments on a gross profit basis. The results of the segments are not necessarily comparable to the results of the corresponding segments of the Group in the previous period.

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2020 (unaudited)

	2020 '000	2019 '000	2020 '000	2019 '000	2020 '000	2019 '000	2020 '000	2019 '000
Segment revenue								
Pharmaceuticals	1,200	2,388	1,301	1,111	1,111	1,200	13,111	13,111
Chemicals	4,224	4,110	4,000	4,000	4,224	(10,844)		
Total	10,000,300	2,188,498	1,331,101	1,331,101	23,444	(10,844)	13,111	13,111
Segment results*								
Pharmaceuticals	1,113	0,400	31,333	31,333	(4,255)	(1,020)	1,333,311	1,333,311
Chemicals	13,300	10,100	1,100	1,100	1,100	30	4,000	4,000
Other	1,040	14,210	3,333	3,333	2,233	30	4,000	4,000
Depreciation and amortisation	12	10,340	1,310	1,310	1,310	(2,100)	1,310	1,310
Impairment losses	(1,330)	(14,120)	(1,400)	(1,400)	(1,400)	2,100	(2,304)	(2,304)
Finance income	2,000	(,433)	(,200)	(,200)	(2,000)		(,100)	(,100)
Finance costs	(4,440)				(,140)		(4,440)	(4,440)
Share of results of associates	32,111	24,021	(31,134)	24,041	(0,400)		32,111	32,111
Income tax							(4,000)	(4,000)
Other								
Total	1,420,200	4,310	14,300	24,041	20,000	1,113	2,301,111	2,301,111
	(313,433)	(,200)	(12,140)	24,041	(23)		(3,200,111)	(3,200,111)
Total	1,114,000	433,000	1,130	24,041	20,000	1,113	1,000,000	1,000,000
Segment assets:								
Pharmaceuticals	41,043,332	1,223	12,111	13,111	4,213,114	(1,131)	1,114	1,114
Chemicals	34,444						3,204	3,204
Other	2,241,111	1,102,000	1,242,333	13,111	2,111,201		21,12,444	21,12,444
Goodwill							4,444	4,444
Intangible assets							1,112	1,112
Total	1,114,000	1,310	2,224	13,111	3,141	(,30,020)	13,111	13,111
							2,411	2,411
Total							40,314,000	40,314,000
Other segment information:								
Other	0	1,100	133,011		1,111		1,311	1,311
Other	(32,211)	4,111	2,333		22,044		41,144	41,144
Other	1,304,444	1,144	3,111		4,333		1,112,200	1,112,200

* Segment results are calculated based on the accounting policies of the Group. The accounting policies of the Group are consistent with the accounting policies of the Group.

** The amounts are calculated based on the accounting policies of the Group. The accounting policies of the Group are consistent with the accounting policies of the Group.

Notes to Interim Condensed Consolidated

30 June 2021

5. REVENUE

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 (Audited)
Revenue from contracts with customer	16,864,028	13,141,811
Revenue from other operations	13,509	13,111
Total revenue	16,877,537	13,154,922

Disaggregated revenue information for revenue from contracts with customer

For the six months ended 30 June 2021 (unaudited)

Segments	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare service RMB'000	Other business operations RMB'000	Total RMB'000
Types of goods or services					
Pharmaceutical manufacturing	11,733,205	2,742,001	37,479	—	14,512,685
Medical devices and medical diagnosis	414,422	76,259	1,804,041	11,459	2,306,181
Healthcare service	30,599	13,951	612	—	45,162
Total	12,178,226	2,832,211	1,842,132	11,459	16,864,028
Geographical markets					
China	8,474,661	1,339,179	1,842,132	10,040	11,666,012
Overseas	3,703,565	1,493,032	—	1,419	5,198,016
Total	12,178,226	2,832,211	1,842,132	11,459	16,864,028
Timing of revenue recognition					
Contract revenue	11,763,804	2,755,952	38,091	—	14,557,847
Revenue from other operations	297,157	13,239	1,804,041	11,459	2,125,896
Revenue from other operations	117,265	63,020	—	—	180,285
Total	12,178,226	2,832,211	1,842,132	11,459	16,864,028

5. REVENUE (Continued)

Disaggregated revenue information for revenue from contracts with customers (Continued)

For the six months ended 30 June 2020 (unaudited)

	2020	2019	2020	2019	2020
	'000	'000	'000	'000	'000
Types of goods or services					
License fee	10,123	2,421,551	2,50		12,015,11
Product sales	23,34	1,01	1,331,14	3,2	1,11,20
Service fee	3	1,014			3
Total	1,242	2,35,4	1,3,4	3,2	13,141
Geographical markets					
China	1,215	1,32,2	1,3,4	2,04	1,0,242
Overseas	2,03	1,311,201		22	4,0,1,1
Total	1,242	2,35,4	1,3,4	3,2	13,141
Timing of revenue recognition					
At a point in time	0	2,43	2,50		12,134,210
Over time	21,01	1,0	1,331,14	3,2	1,11,001
	3	31,44			20
Total	1,242	2,35,4	1,3,4	3,2	13,141

Notes to Interim Condensed Consolidated

30 June 2021

6. OTHER INCOME

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 ()
Interest income	8,009	20,311
Dividend income	132,660	1,113
Other income	1,045	1,111
Total	141,714	110,422

7. OTHER GAINS

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 ()
Gain on disposal of subsidiaries	279,501	1,220
Gain on disposal of investment properties	1,182,759	23,344
Gain on disposal of other assets	47,549	41,000
Gain on disposal of other investments	78,995	
Other gains	56,451	311
Total	1,645,255	33,222

8. FINANCE COSTS

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 ()
Interest expense	413,098	42,111
Finance charges	14,841	12,111
Finance income	(7,214)	(1,111)
Total	420,725	42,111

9. PROFIT BEFORE TAX

本集团利润总额为人民币10,166千元(2020年:人民币(1,211)千元)

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 ()
营业收入	6,433,620	4,320,000
营业成本	1,677,258	1,252,200
毛利	4,756,362	3,067,800
其他收益(包括政府补助、公允价值变动收益、投资收益等)	3,070,335	2,415,200
其他收入	180,142	14,300
其他费用	101,061	13,000
公允价值变动收益	39,619	3,100
利润总额	3,391,157	2,410,100
所得税费用	1,494,528	1,110,400
净利润	1,896,629	1,300,000
其他综合收益	21,673	12,300
公允价值变动收益	564,429	40,400
其他综合收益	101,351	1,000
其他综合收益	279,667	24,240
其他综合收益	16,953	(100)
其他综合收益	15,022	40,000
其他综合收益	(218)	2,000
其他综合收益	190,379	
其他综合收益	(1,182,759)	(23,340)
其他综合收益	(47,549)	(41,000)
其他综合收益	(41,939)	(1,100)
其他综合收益	10,166	(1,211)

Notes to Interim Condensed Consolidated

30 June 2021

10. INCOME TAX

Income tax expense for the six months ended 30 June 2021 is RMB198,710 thousand (2020: RMB451,937 thousand). The effective tax rate for the six months ended 30 June 2021 is 20.1% (2020: 23.1%).

The income tax expense for the six months ended 30 June 2021 is primarily attributable to the income tax payable on the profit before tax of RMB987,100 thousand (2020: RMB1,965,500 thousand) at the statutory rate of 25% (2020: 25%). The income tax expense is lower than the amount calculated at the statutory rate of 25% (2020: 25%) due to the following factors:

- The income tax expense is reduced by RMB288,190 thousand (2020: RMB513,563 thousand) due to the effect of the income tax credit for the income tax payable on the profit before tax.
- The income tax expense is reduced by RMB10,200 thousand (2020: RMB10,200 thousand) due to the effect of the income tax credit for the income tax payable on the profit before tax.
- The income tax expense is reduced by RMB10,200 thousand (2020: RMB10,200 thousand) due to the effect of the income tax credit for the income tax payable on the profit before tax.

The income tax expense for the six months ended 30 June 2021 is RMB198,710 thousand (2020: RMB451,937 thousand).

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 (Audited)
Income tax expense	198,710	451,937
Income tax credit	(288,190)	(513,563)
Income tax payable	550,647	3,201,100

11. DIVIDENDS

On 30 June 2021, the Board of Directors proposed a final dividend of RMB0.43 per share for the six months ended 30 June 2021.

The dividend is payable on 11 July 2021. The dividend is payable to the shareholders of record as at 31 June 2021.

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

本公司于2021年6月30日及2020年6月30日归属于普通股股东的净利润分别为人民币2,482,373千元及人民币1,141,100千元。

本公司于2021年6月30日及2020年6月30日归属于普通股股东的净利润分别为人民币2,482,373千元及人民币1,141,100千元。本公司于2021年6月30日及2020年6月30日归属于普通股股东的净利润分别为人民币2,482,373千元及人民币1,141,100千元。

本公司于2021年6月30日及2020年6月30日归属于普通股股东的净利润分别为人民币2,482,373千元及人民币1,141,100千元。

	For the six months ended 30 June	
	2021 RMB'000 (unaudited)	2020 '000 ()
Earnings		
归属于普通股股东的净利润	2,482,373	1,141,100
归属于普通股股东的净利润	2,482,373	1,141,100

	Number of shares For the six months ended 30 June	
	2021 (unaudited)	2020 ()
Shares		
归属于普通股股东的净利润	2,562,898,545	2,281,140,400
归属于普通股股东的净利润	2,562,898,545	2,281,140,400

本公司于2021年6月30日及2020年6月30日归属于普通股股东的净利润分别为人民币2,482,373千元及人民币1,141,100千元。

Notes to Interim Condensed Consolidated

30 June 2021

13. PROPERTY, PLANT AND EQUIPMENT

	For the six months ended	
	30 June	
	2021	2020
	RMB'000	'000
	(Unaudited)	()
Cost	12,579,873	10,200,000
Accumulated depreciation	1,481,681	1,111,240
Accumulated impairment losses	790	14,300
Depreciation expense	(46,840)	(1,300)
Impairment losses	(1,434,727)	(40,400)
Disposal	(564,429)	(4,300)
Net book value	(29,439)	(4,300)
At 30 June	11,986,909	11,313,400

At 30 June 2021, the net book value of property, plant and equipment is RMB11,986,909 (31 December 2020: RMB11,313,400). The net book value is lower than the carrying amount of RMB11,986,909 (31 December 2020: RMB11,313,400) due to the impairment losses of RMB1,434,727 (31 December 2020: RMB40,400) and disposal of RMB564,429 (31 December 2020: RMB4,300).

14. TRADE AND BILLS RECEIVABLES

	30 June	
	2021	
	RMB'000	2020
	(Unaudited)	'000
	()	()
Trade receivables	5,989,288	4,400,000
Bills receivable	38,949	242,400
Net book value	6,028,237	4,642,400

At 30 June 2021, the net book value of trade and bills receivables is RMB6,028,237 (31 December 2020: RMB4,642,400). The net book value is lower than the carrying amount of RMB6,028,237 (31 December 2020: RMB4,642,400) due to the impairment losses of RMB1,434,727 (31 December 2020: RMB40,400) and disposal of RMB564,429 (31 December 2020: RMB4,300).

14. TRADE AND BILLS RECEIVABLES (Continued)

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Trade receivables	5,983,688	4,441,300
1. Trade receivables	144,645	1,300,000
2. Bills receivable	13,640	42,000
3. Other receivables	140,781	121,300
Less: Allowance for doubtful debts	(293,466)	(2,000,000)
	5,989,288	4,441,300
At 30 June 2021, the carrying amount of trade receivables is 4,300,000 (2020: 4,300,000)		

15. TRADE AND BILLS PAYABLES

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Trade payables	3,208,429	2,420,000
Bills payable	537,155	34,300
	3,745,584	3,228,000

Notes to Interim Condensed Consolidated

30 June 2021

15. TRADE AND BILLS PAYABLES (Continued)

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Trade payables	3,152,144	2,881,111
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100.	39,361	44,200
Trade bills payable	12,770	1,000
Other payables	4,154	1,000
	3,208,429	2,427,311

16. INTEREST-BEARING BANK AND OTHER BORROWINGS

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Bank borrowings	(1)	1,043,311
Other borrowings	1,302,115	1,244,311
	16,335,918	17,638,033
Bank borrowings	(2)	1,344,240
Other borrowings	(3)	20,100
	1,500,000	1,564,340
	5,227,887	1,564,340
	24,365,920	22,448,311
	(15,852,411)	(14,415,741)
	8,513,509	8,532,570

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
1	15,852,411	14,411,4
2	2,664,956	,42,33
3	4,226,672	2,3
4	1,621,881	,3
	24,365,920	22,4,31
	(15,852,411)	(14,411,4)
	8,513,509	1,4,1

(1) Bank loans

1	0.3000%	0.200%	(31	2020	0.3000%	0.2000%)
2	30	2021,	4,226,000 (31	2020	1,114,200),	(13)
3	30	2021,	4,300,000 (31	2020	4,300,000)	
4	30	2021,	30,000,000 (31	2020)	
5	30	2021,	32,400,000 (31	2020)	
6	30	2021,	3,000 (31	2020)	

(2) Super Short-term Commercial Paper

1	2	2021,	1,000,000,000	2.0%
2	22	2021,		

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

(Continued)

(3) Corporate bonds

14	RMB 201,000,000	4.0%	1,000,000	3.4%	1,200,000,000	14	2022	14	2020
RMB 2022, 14, 2022.									
2021.									
13	RMB 201,000,000	10%			1,300,000,000	13	2023		30
RMB 2021, 30, 2021.									
30	RMB 201,000,000		1,000,000,000	4.4%	1,000,000,000				30
RMB 2022, 2, 2020, 2,000,000									
RMB 2022, 30, 2023.									
RMB 2021, 30									
2	RMB 201,000,000	3.1%			1,000,000,000				2
RMB 202, 2									

17. BUSINESS COMBINATION

2	RMB 2021, 0	100%							
* (深圳信生藥業有限公司) (RMB 3,400,000)									
100%									
1	RMB 2021, 0	0%							
* (上海星苑達醫療科技有限公司) (RMB 22,400,000)									
0%									
* (上海星苑達醫療科技有限公司) (RMB 22,400,000)									

17. BUSINESS COMBINATION (Continued)

		Fair value recognised on acquisition '000)
		2,800
		34,300
		34,300
		0
		(4,410)
		(4,420)
		3,400
		(,000)
		2,800
		2,800
		'000)
		(12,000)
		0
		(,800)
		(1,400)
		(21,300)

Notes to Interim Condensed Consolidated

30 June 2021

17. BUSINESS COMBINATION (Continued)

	'000
1 July 2021	1,034,400
30 June 2021	1,032,000
1 July 2021	(3,000)
30 June 2021	(3,000)
1 July 2021	1,240,000
30 June 2021	1,221,000
1 July 2021	2,100,000
30 June 2021	2,300,000

18. DISPOSAL OF SUBSIDIARIES

100% ownership	30 June 2021, RMB	3,400,000	(遠東腸衣食品有限公司)
70% ownership	30 June 2021, RMB	31,400,000	(台州市立浙東醫養投資管理有限公司)

18. DISPOSAL OF SUBSIDIARIES (Continued)

Item	2020	2021
On December 31, 2020, the Group held 100% equity interest in Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.). The Group disposed of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on December 31, 2020, and the disposal price was 1,113,000 RMB.		
On December 31, 2021, the Group held 100% equity interest in Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.). The Group disposed of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on December 31, 2021, and the disposal price was 3,388,000 RMB.		
* The Group disposed of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on December 31, 2021, and the disposal price was 3,388,000 RMB.		

Notes to Interim Condensed Consolidated

30 June 2021

18. DISPOSAL OF SUBSIDIARIES (Continued)

	'000
Gain on disposal of subsidiaries	11,120
Gain on disposal of subsidiaries, net of income tax	34,733
Loss on disposal of subsidiaries, net of income tax	(10,064)
Net gain on disposal of subsidiaries, net of income tax	23,669

19. COMMITMENTS

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Contractual commitments	2,334,273	2,244,244
Contractual commitments, net of income tax	834,921	810,333
Contractual commitments, net of income tax, excluding the amount expected to be settled within 12 months	498,805	342,111
Contractual commitments, net of income tax, excluding the amount expected to be settled within 12 months, net of non-current assets	3,193,706	4,003,222
Contractual commitments, net of income tax, excluding the amount expected to be settled within 12 months, net of non-current assets, net of non-current liabilities	6,861,705	8,216,444


20. RELATED PARTY TRANSACTIONS

(a) Sales of pharmaceutical products and services

	For the six months ended	
	2021	2020
	RMB'000	'000
	(Unaudited)	
...	1,809,891	1,333,32
...	326,501	1,113,33
...	7,936	4,030
...	5,139	
...	2,436	
...	2,039	3
...	2,030	14
...	1,251	1,
...	671	40
...	637	2,
...	252	1,
...	148	4,31
...	40	4,4 1
...	26	13
...	19	1
...	6	1,
...	6	1
...	4	42
...	3	3
...	—	2,
...	—	,03
...	—	1, 12
...	—	1,2 2
	2,159,035	1, 2, 1

20. RELATED PARTY TRANSACTIONS (Continued)

(b) Purchase of pharmaceutical products and services



20. RELATED PARTY TRANSACTIONS (Continued)

(c) Leasing and property management services (Continued)

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000
As lessee		
Leasing services (3 & 5 & 13 & 16)	5,242	2, 2
Property management services (5 &)	114	11
Other services (5 &)	41	43
	5,397	3,112

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000
Property management services		
Property management services (3 & 5 & 14 & 16)	6,818	, 04

(d) Loans from/to a related parties

	30 June	
	2021 RMB'000 (Unaudited)	2020 '000
Deposits in Fosun Finance		
Deposits in Fosun Finance (3 & 16)	965,024	44 , 0

Notes to Interim Condensed Consolidated

30 June 2021

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
A loan from a related party		
From a related party (Note 3 & 16)	73,450	1,300

The loan from a related party is unsecured, interest-free and has a term of 12 months. The loan is denominated in RMB. The interest rate is 3% per annum. The loan is repayable on demand.

The loan from a related party is unsecured, interest-free and has a term of 12 months. The loan is denominated in RMB. The interest rate is 10% per annum. The loan is repayable on demand.

The loan from a related party is unsecured, interest-free and has a term of 12 months. The loan is denominated in RMB. The interest rate is 3% per annum. The loan is repayable on demand.

The loan from a related party is unsecured, interest-free and has a term of 12 months. The loan is denominated in RMB. The interest rate is 4.2% per annum. The loan is repayable on demand.

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Loans to related parties		
To a related party (Note 1)	5,814	1,300
To a related party (Note 2)	188,840	1,140
To a related party (Note 1)	7,691	-
	202,345	2,440

(e) Interest income from/interest expense to related parties

	Six months ended 30 June 2021 RMB'000 (Unaudited)	2020 '000 ()
Interest income		
From a related party (Note 2)	4,678	4,000
From a related party (Note 3 & 16)	4,560	3,300
From a related party (Note 1)	182	-
From a related party (Note 1)	112	1,000
	9,532	8,300

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (continued)

0.3% (2020 0.3%),
 1.1% (2020 1.1%),
 1.1% (2020 1.1%)

	Six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000
Interest expense		
(3 & 16)	1,432	1,015

- (1) ...
- (2) ...
- (3) ...
- (4) ...
- (5) ...
- (6) ...
- (7) ...
- (8) ...
- (9) ... 2021, ... 100%
- (10) ...
- (11) ...

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (continued)

(continued)

(12)	Interest income from related parties	14,000	14,000
(13)	Interest expense to related parties	(14,000)	(14,000)
(14)	Interest income from related parties	14,000	14,000
(1)	Interest expense to related parties	(14,000)	(14,000)
(1)	Interest income from related parties	14,000	14,000
(1)	Interest expense to related parties	(14,000)	(14,000)

(1) Interest income from related parties for the six months ended 30 June 2021, 2020, and 2019 is nil.

(f) Compensation of key management personnel of the Group

	Six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 (Audited)
Key management personnel of the Group	49,724	0,011
Key management personnel of subsidiaries	17,451	1,410
Key management personnel of associates	526	243
Total	67,701	1,664

(g) Guarantees

	Guarantee amount	Start date	End date	Fulfilled or not
Guarantee provided to related parties	10 ⁵ , 2,000	2021/1/22	2021/12/2	
Guarantee provided to other parties	43, 0, 000	2021/1/1	2021/12/2	

As at 30 June 2021, the Group has provided guarantees of RMB105,200,000 to related parties and RMB43,000,000 to other parties. The Group has not provided any guarantees to related parties or other parties as at 30 June 2020.

20. RELATED PARTY TRANSACTIONS (Continued)

(h) Donations

	Six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000
	8,708	1,000

截至2021年6月30日止六个月的捐赠金额为人民币8,708,000元(截至2020年6月30日止六个月的捐赠金额为人民币1,000,000元)。

(i) Outstanding balances with related parties:

()	截至2021年6月30日止六个月的应付关联方款项为人民币1,322,200元(截至2020年6月30日止六个月的应付关联方款项为人民币434,000元)。	
()	截至2021年6月30日止六个月的应付关联方款项为人民币1,002,230元(截至2020年6月30日止六个月的应付关联方款项为人民币2,000元)。	
()	截至2021年6月30日止六个月的应付关联方款项为人民币12,140元(截至2020年6月30日止六个月的应付关联方款项为人民币1,000元)。	
()	截至2021年6月30日止六个月的应付关联方款项为人民币4,041,000元(截至2020年6月30日止六个月的应付关联方款项为人民币2,000元)。	
()	截至2021年6月30日止六个月的应付关联方款项为人民币1,440,000元(截至2020年6月30日止六个月的应付关联方款项为人民币132,000元)。	
()	截至2021年6月30日止六个月的应付关联方款项为人民币23,230元(截至2020年6月30日止六个月的应付关联方款项为人民币303,000元)。	
()	截至2021年6月30日止六个月的应付关联方款项为人民币43,000元(截至2020年6月30日止六个月的应付关联方款项为人民币44,000元)。	
()	截至2021年6月30日止六个月的应付关联方款项为人民币10,300元(截至2020年6月30日止六个月的应付关联方款项为人民币13,000元)。	

20. RELATED PARTY TRANSACTIONS (Continued)**(i) Outstanding balances with related parties: (Continued)**

()

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

	Carrying amounts		Fair values	
	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Financial Assets:				
Financial assets at fair value through profit or loss	6,243	1,043	6,243	1,043
Financial assets at fair value through other comprehensive income	472,998	2,411	472,998	2,411
Financial assets at fair value through profit or loss	4,726,982	3,430	4,726,982	3,430
Financial assets at fair value through profit or loss	294,076	1,140	297,354	1,140
	5,500,299	4,242	5,503,577	4,242
Financial liabilities:				
Financial liabilities at fair value through profit or loss	6,674,021	14,114	6,694,426	12,111
Financial liabilities at fair value through profit or loss	5,227,887	3,2010	5,195,438	3,3003
Financial liabilities at fair value through profit or loss	248,335	241,3	248,335	241,3
Financial liabilities at fair value through profit or loss	71,200	3,03	71,200	3,03
	12,221,443	14,012	12,209,399	14,103

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

As at 30 September 2021, the fair value of the financial instruments is as follows:

Item	30 September 2021
Financial assets	1,123,810,165
Financial liabilities	(1,123,810,165)
Total	0

The fair value of the financial instruments is determined based on the fair value hierarchy. The fair value of the financial instruments is determined based on the fair value hierarchy.

The fair value of the financial instruments is determined based on the fair value hierarchy. The fair value of the financial instruments is determined based on the fair value hierarchy.

30 2021

The fair value of the financial instruments is determined based on the fair value hierarchy. The fair value of the financial instruments is determined based on the fair value hierarchy.

30 2021

Unobservable inputs for Level 3 assets

The fair value of the financial instruments is determined based on the fair value hierarchy. The fair value of the financial instruments is determined based on the fair value hierarchy.

The fair value of the financial instruments is determined based on the fair value hierarchy. The fair value of the financial instruments is determined based on the fair value hierarchy.

Notes to Interim Condensed Consolidated

30 June 2021

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Unobservable inputs for Level 3 liabilities

Financial assets measured at fair value	1,200,000 (31 December 2020)
Financial liabilities measured at fair value	(3,033,000) (31 December 2020)

Fair value hierarchy

The following table shows the fair value hierarchy of the financial instruments measured at fair value:

Assets measured at fair value:

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Financial assets measured at fair value	3,017,461	206,237	1,503,284	4,726,982
Financial liabilities measured at fair value	—	6,243	—	6,243
Financial assets and liabilities measured at fair value	—	472,998	—	472,998
Total	3,017,461	685,478	1,503,284	5,206,223
Financial assets measured at fair value	(1,111)	(1,120)	(1,130)	(3,361)
Financial liabilities measured at fair value	—	—	—	—
Financial assets and liabilities measured at fair value	—	—	—	—
Total	(1,111)	(1,120)	(1,130)	(3,361)
Financial assets measured at fair value	1,211,411	101,310	1,140,210	3,452,931
Financial liabilities measured at fair value	—	1,043	—	1,043
Financial assets and liabilities measured at fair value	—	2,881	—	2,881
Total	1,211,411	1,331,310	1,140,210	4,005,962

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value: (Continued)

		30 2021	
		Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
At 2021	1	1,514,028	—
Decrease due to:		(159,575)	—
Decrease due to:		(9,123)	—
Decrease due to:		191,582	—
Decrease due to:		(33,628)	—
At 2021	30	1,503,284	—
		30 2020	
At 2020	1	1,224	3,24
Decrease due to:		114	—
Decrease due to:		—	24
Decrease due to:		13	—
Decrease due to:		(321)	—
Decrease due to:		21	—
At 2020	30	1,400	30

At 2020, the fair value of equity investments designated at fair value through other comprehensive income was RMB34,000,000, which was measured at fair value based on the quoted price in the Shanghai Stock Exchange. At 2021, the fair value of equity investments designated at fair value through other comprehensive income was RMB21,100,000, which was measured at fair value based on the quoted price in the Shanghai Stock Exchange.

Notes to Interim Condensed Consolidated

30 June 2021

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value:

	Fair value measurement using			Total RMB'000
	Quoted prices in active Markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
As at 30 June 2021 (RMB'000)	—	—	71,200	71,200
As at 31 December 2020 (RMB'000)	(1,000)	(1,200)	(1,300)	(3,500)
As at 30 June 2020 (RMB'000)	—	—	3,003	3,003

	Six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 (Audited)
As at 1 January	73,503	2,431,244
Changes during the period	(2,303)	3,02
	—	(20,244)
As at 30 June	71,200	2,434,022

The fair value of the liabilities measured at fair value is determined using the market price of the liabilities at the reporting date. The fair value of the liabilities measured at fair value is determined using the market price of the liabilities at the reporting date.

22. CONTINGENT LIABILITIES

As at 30 June 2021, the Group has no contingent liabilities.

23. EVENTS AFTER THE REPORTING PERIOD

Sold back of the "18 Fosun Pharma 01" Corporate Bonds

On 12 July 2021, the Group sold back 100 million RMB of the "18 Fosun Pharma 01" Corporate Bonds (the "Bonds") issued by Fosun Pharmaceutical (Group) Co., Ltd. (the "Company") on 12 July 2021. The Bonds were sold back at a price of 100.00% of the face value. The Group received a net cash of 100 million RMB from the sale of the Bonds, after deducting the transaction costs of 4,000 RMB. The Bonds were sold back at a price of 100.00% of the face value, which is higher than the carrying amount of 99,996,000 RMB as at 30 June 2021. The gain of 4,000 RMB is recognized in the profit or loss for the period.

Placing of new shares of Sisram Medical Ltd

On 24 July 2021, the Group placed 24,000,000 new shares of Sisram Medical Ltd (the "Company") at a price of 4.00 RMB per share. The total proceeds from the placement of new shares are 96,000,000 RMB, after deducting the transaction costs of 4,000 RMB. The Company's net assets and equity are increased by 96,000,000 RMB.

24. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The interim condensed consolidated financial statements for the period ended 30 June 2021 were approved by the Board of Directors on 23 July 2021.

Definitions

<p>「中國證監會」指 中國證券監督管理委員會，其辦事處設於北京，為中國政府監管證券市場之主要機構。</p>	<p>* (中國證券監督管理委員會)，其辦事處設於北京，為中國政府監管證券市場之主要機構。</p>
<p>「()」指 ()</p>	<p>()</p>
<p>「遠東」指 遠東食品有限公司</p>	<p>* (遠東腸衣食品有限公司)</p>
<p>「佛山復星禪誠醫院有限公司」指 佛山復星禪誠醫院有限公司</p>	<p>* (佛山復星禪誠醫院有限公司)， * (佛山市禪城區中心醫院有限公司)， * (佛山市禪城區中心醫院有限公司)， (佛山市禪城區人口和衛生藥品監督管理局)，</p>
<p>「佛山禪曦房地產開發有限公司」指 佛山禪曦房地產開發有限公司</p>	<p>* (佛山禪曦房地產開發有限公司)</p>
<p>「上海復星醫療系統有限公司」指 上海復星醫療系統有限公司</p>	<p>* (上海復星醫療系統有限公司)，</p>
<p>「上海復星健康科技(集團)有限公司」指 上海復星健康科技(集團)有限公司</p>	<p>* (上海復星健康科技(集團)有限公司)， * (上海復星醫療(集團)有限公司)，</p>
<p>「上海復星高科技(集團)有限公司」指 上海復星高科技(集團)有限公司</p>	<p>* (上海復星高科技(集團)有限公司)， 14.0 (1)</p>
<p>「復星控股有限公司」指 復星控股有限公司</p>	<p>(復星控股有限公司)，</p>
<p>「復星國際控股有限公司」指 復星國際控股有限公司</p>	<p>(復星國際控股有限公司)， 2.2 % 14.1%</p>
<p>「復星國際有限公司」指 復星國際有限公司</p>	<p>(復星國際有限公司)， ()</p>
<p>「復星凱特生物科技有限公司」指 復星凱特生物科技有限公司</p>	<p>* (復星凱特生物科技有限公司)，</p>
<p>「上海復星醫藥產業發展有限公司」指 上海復星醫藥產業發展有限公司</p>	<p>* (上海復星醫藥產業發展有限公司)，</p>

Definitions

◀ 中國	◀ 中國
◀ 公司	◀ 本公司
◀ 董事	◀ 董事會
◀ 股東	◀ 股東大會
◀ 上市規則	◀ 上海證券交易所股票上市規則
◀ 10%	◀ 10%
◀ 國家藥品監督管理局	◀ 中華人民共和國國家藥品監督管理局
◀ 重慶醫工院製藥有限責任公司	◀ 重慶醫工院製藥有限責任公司
◀ &	◀ 及
◀ 2021年3月31日	◀ 2021年3月31日
◀ 重慶醫工院製藥有限責任公司	◀ 重慶醫工院製藥有限責任公司
◀ 上海博億雅醫療器械有限責任公司	◀ 上海博億雅醫療器械有限責任公司
◀ 上海復宏漢霖生物技術股份有限公司	◀ 上海復宏漢霖生物技術股份有限公司
◀ 上海礪麟醫療管理合夥企業(有限合夥)	◀ 上海礪麟醫療管理合夥企業(有限合夥)
◀ 《上海證券交易所股票上市規則》	◀ 《上海證券交易所股票上市規則》
◀ 上海證券交易所	◀ 上海證券交易所
◀ ()"	◀ ()"
◀ 1.00	◀ 1.00
◀ 瀋陽天晟達商貿有限公司	◀ 瀋陽天晟達商貿有限公司

...	... * (深圳信生藥業有限公司),
...	... * (廣東匯信藥業有限公司),
...	... * (國藥產業投資有限公司),
...	... * (國藥控股股份有限公司),
...	... (010)
...	... (01)
...	...
...	...
...	...
...	...
...	... * (宿遷市鐘吾醫院有限責任公司)/
...	... * (宿遷市腫瘤醫院),
...	... * (台州市投資有限公司)
...	... * (台州浙東醫養投資管理有限公司)
...	...
...	...
...	...
...	...
...	...
...	... * (江蘇萬邦雲健康科技有限公司),
...	... * (江蘇萬邦生化醫藥集團有限責任公司),
...	... * (瀋陽萬邦天晟生物科技有限公司),
...	...
...	... * (《董事/有關僱員進行證券交易的書面指引》)

Definitions

... (武漢濟和醫院有限公司), ...

... (上海星苑達醫療科技有限公司), ...

... (徐州星晨婦兒醫院有限公司), ...

... (重慶藥友製藥有限責任公司), ...

... (上海豫園旅遊商城(集團)股份有限公司), ... (00)

...